| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Antineoplastic Combined Chemotherapy Protocols | 34 | 1999 | 121 |
Why?
|
Lymphoma, Non-Hodgkin | 24 | 1999 | 41 |
Why?
|
Antibodies, Monoclonal | 30 | 2002 | 241 |
Why?
|
Lymphoma, Follicular | 16 | 1999 | 27 |
Why?
|
Antineoplastic Agents | 21 | 2000 | 190 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 14 | 1999 | 38 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 28 | 2002 | 33 |
Why?
|
Lymphoma, B-Cell | 10 | 1999 | 33 |
Why?
|
Hodgkin Disease | 14 | 2002 | 46 |
Why?
|
Nitrogen Mustard Compounds | 8 | 2007 | 10 |
Why?
|
Lymphoma | 8 | 2003 | 96 |
Why?
|
Radioimmunotherapy | 7 | 2004 | 6 |
Why?
|
Salvage Therapy | 8 | 2007 | 37 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2004 | 28 |
Why?
|
Humans | 95 | 1981 | 1856 |
Why?
|
Treatment Outcome | 26 | 1999 | 661 |
Why?
|
Neoplasms, Second Primary | 6 | 1999 | 31 |
Why?
|
Boronic Acids | 6 | 2007 | 16 |
Why?
|
Pyrazines | 6 | 2007 | 20 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2001 | 118 |
Why?
|
Drug Resistance, Neoplasm | 8 | 2005 | 32 |
Why?
|
Clinical Trials as Topic | 13 | 2004 | 251 |
Why?
|
Immunotherapy | 5 | 2000 | 48 |
Why?
|
Middle Aged | 42 | 1981 | 1161 |
Why?
|
Burkitt Lymphoma | 2 | 2008 | 36 |
Why?
|
Adult | 41 | 1981 | 1317 |
Why?
|
Bone Marrow Transplantation | 7 | 1999 | 90 |
Why?
|
Combined Modality Therapy | 13 | 1999 | 219 |
Why?
|
Stem Cell Transplantation | 6 | 2006 | 50 |
Why?
|
Doxorubicin | 6 | 2003 | 60 |
Why?
|
Aged | 29 | 1981 | 988 |
Why?
|
Deoxycytidine | 4 | 2003 | 20 |
Why?
|
Hematopoietic Stem Cell Transplantation | 8 | 1999 | 49 |
Why?
|
Male | 42 | 1993 | 1553 |
Why?
|
Antigens, CD20 | 5 | 2003 | 12 |
Why?
|
Medical Oncology | 3 | 2008 | 28 |
Why?
|
Female | 44 | 1981 | 1643 |
Why?
|
Survival Rate | 13 | 1999 | 250 |
Why?
|
Vidarabine | 4 | 2004 | 17 |
Why?
|
Transplantation, Autologous | 11 | 1999 | 78 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2007 | 7 |
Why?
|
Amifostine | 2 | 2004 | 15 |
Why?
|
Recurrence | 11 | 1998 | 261 |
Why?
|
Protease Inhibitors | 3 | 2007 | 39 |
Why?
|
Disease-Free Survival | 10 | 2000 | 102 |
Why?
|
Cytoprotection | 2 | 2004 | 32 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2011 | 35 |
Why?
|
Immunologic Factors | 4 | 2006 | 46 |
Why?
|
Pyridines | 2 | 2009 | 61 |
Why?
|
Oxazines | 1 | 2009 | 16 |
Why?
|
Heart Neoplasms | 1 | 2009 | 17 |
Why?
|
Cyclophosphamide | 7 | 1999 | 82 |
Why?
|
Toll-Like Receptor 9 | 1 | 2009 | 14 |
Why?
|
Survival Analysis | 9 | 1998 | 205 |
Why?
|
Heart Atria | 1 | 2009 | 37 |
Why?
|
Protein Kinase Inhibitors | 1 | 2009 | 59 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2003 | 17 |
Why?
|
B-Lymphocytes | 4 | 2002 | 134 |
Why?
|
Agammaglobulinemia | 1 | 2008 | 14 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2009 | 73 |
Why?
|
Oligodeoxyribonucleotides | 2 | 2004 | 86 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2009 | 77 |
Why?
|
B-Lymphocyte Subsets | 1 | 2008 | 33 |
Why?
|
Neoplasm Staging | 7 | 2003 | 125 |
Why?
|
Esophageal Neoplasms | 1 | 2009 | 37 |
Why?
|
Neoplasm Proteins | 1 | 2009 | 110 |
Why?
|
Tomography, Emission-Computed | 2 | 2003 | 25 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2008 | 67 |
Why?
|
Lymphocyte Depletion | 2 | 2002 | 29 |
Why?
|
Drug Resistance | 2 | 2005 | 83 |
Why?
|
Prognosis | 8 | 1999 | 388 |
Why?
|
Immunoglobulin G | 1 | 2008 | 191 |
Why?
|
Aged, 80 and over | 10 | 2002 | 599 |
Why?
|
Whole-Body Irradiation | 2 | 2001 | 43 |
Why?
|
Follow-Up Studies | 11 | 1995 | 553 |
Why?
|
Eosinophilia | 2 | 1993 | 24 |
Why?
|
Antibodies, Neoplasm | 3 | 2008 | 28 |
Why?
|
Clozapine | 2 | 1993 | 17 |
Why?
|
Gallium | 1 | 2004 | 5 |
Why?
|
Immunoconjugates | 1 | 2004 | 11 |
Why?
|
Interferon-beta | 1 | 2004 | 26 |
Why?
|
Interferon-alpha | 1 | 2004 | 43 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 210 |
Why?
|
Myelodysplastic Syndromes | 2 | 1999 | 27 |
Why?
|
Risk Factors | 10 | 1993 | 555 |
Why?
|
Tympanoplasty | 1 | 2001 | 2 |
Why?
|
Pleural Neoplasms | 1 | 2001 | 18 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2006 | 176 |
Why?
|
Adenoidectomy | 1 | 2001 | 9 |
Why?
|
Pneumonia | 1 | 2003 | 85 |
Why?
|
Tonsillectomy | 1 | 2001 | 12 |
Why?
|
Mesothelioma | 1 | 2001 | 22 |
Why?
|
Interleukin-2 | 1 | 2002 | 71 |
Why?
|
Thalidomide | 2 | 2010 | 12 |
Why?
|
Neoplasms | 2 | 2005 | 239 |
Why?
|
Photochemotherapy | 1 | 2001 | 18 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2010 | 17 |
Why?
|
Trans-Activators | 1 | 2004 | 113 |
Why?
|
Vincristine | 4 | 2004 | 27 |
Why?
|
Somatostatin | 1 | 1999 | 15 |
Why?
|
Cytarabine | 3 | 2004 | 32 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2008 | 31 |
Why?
|
Sarcoma | 1 | 1999 | 42 |
Why?
|
Vinblastine | 3 | 2003 | 22 |
Why?
|
Drug Administration Schedule | 4 | 2002 | 191 |
Why?
|
Vitamin D | 2 | 2009 | 41 |
Why?
|
Prednisone | 4 | 2004 | 80 |
Why?
|
Otitis Media | 1 | 2001 | 34 |
Why?
|
DNA-Binding Proteins | 1 | 2004 | 204 |
Why?
|
Incidence | 6 | 1993 | 336 |
Why?
|
Ultraviolet Rays | 2 | 2009 | 76 |
Why?
|
Melphalan | 2 | 2004 | 24 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2008 | 31 |
Why?
|
Carmustine | 2 | 2004 | 25 |
Why?
|
Etoposide | 2 | 2004 | 37 |
Why?
|
Cohort Studies | 4 | 1999 | 332 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1999 | 86 |
Why?
|
Practice Guidelines as Topic | 2 | 2010 | 174 |
Why?
|
Antidepressive Agents | 1 | 1998 | 46 |
Why?
|
Depressive Disorder | 2 | 1993 | 76 |
Why?
|
T-Lymphocytes | 3 | 2002 | 182 |
Why?
|
Dose-Response Relationship, Drug | 4 | 1999 | 431 |
Why?
|
Child | 9 | 1981 | 749 |
Why?
|
Retrospective Studies | 6 | 1994 | 653 |
Why?
|
Drug Synergism | 3 | 2009 | 104 |
Why?
|
Colitis | 1 | 1995 | 14 |
Why?
|
Remission Induction | 5 | 2001 | 64 |
Why?
|
Polymerase Chain Reaction | 3 | 1999 | 279 |
Why?
|
Young Adult | 4 | 2009 | 380 |
Why?
|
Branchial Region | 1 | 1993 | 4 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 2 | 2002 | 14 |
Why?
|
Foreign Bodies | 1 | 1994 | 36 |
Why?
|
Bronchi | 1 | 1994 | 45 |
Why?
|
Trachea | 1 | 1994 | 50 |
Why?
|
Antipsychotic Agents | 1 | 1995 | 49 |
Why?
|
Flow Cytometry | 2 | 2004 | 216 |
Why?
|
Esophagus | 1 | 1994 | 49 |
Why?
|
Apoptosis | 3 | 2005 | 265 |
Why?
|
Psychotic Disorders | 1 | 1993 | 38 |
Why?
|
Hospitals, County | 1 | 1992 | 1 |
Why?
|
Age Factors | 3 | 2001 | 480 |
Why?
|
Hospitals, General | 1 | 1992 | 13 |
Why?
|
Adolescent | 8 | 1981 | 891 |
Why?
|
Immunophenotyping | 3 | 2002 | 66 |
Why?
|
Cancer Vaccines | 2 | 2007 | 21 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 1999 | 30 |
Why?
|
Mitoxantrone | 2 | 2004 | 9 |
Why?
|
Graft vs Host Disease | 2 | 2002 | 29 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2009 | 48 |
Why?
|
Cell Separation | 2 | 2002 | 110 |
Why?
|
Postoperative Complications | 2 | 2001 | 305 |
Why?
|
Signal Transduction | 4 | 2005 | 313 |
Why?
|
Infant | 6 | 1981 | 464 |
Why?
|
Referral and Consultation | 2 | 1994 | 134 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2008 | 61 |
Why?
|
Gastrointestinal Tract | 1 | 2011 | 26 |
Why?
|
Disease Progression | 2 | 2003 | 244 |
Why?
|
Methylprednisolone | 1 | 2011 | 41 |
Why?
|
Radiology | 1 | 2011 | 15 |
Why?
|
United States | 6 | 2004 | 604 |
Why?
|
Pancytopenia | 1 | 2010 | 13 |
Why?
|
Maximum Tolerated Dose | 1 | 2010 | 18 |
Why?
|
Mucositis | 1 | 2010 | 12 |
Why?
|
Child, Preschool | 7 | 1981 | 554 |
Why?
|
Patient Selection | 2 | 2007 | 155 |
Why?
|
Transplantation Conditioning | 1 | 2010 | 23 |
Why?
|
Arabinonucleosides | 1 | 2010 | 2 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2010 | 3 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2010 | 14 |
Why?
|
Acute Disease | 2 | 1993 | 271 |
Why?
|
Adenine Nucleotides | 1 | 2010 | 15 |
Why?
|
Genes, Immunoglobulin | 1 | 2010 | 28 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 89 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2010 | 24 |
Why?
|
Hydroxamic Acids | 1 | 2010 | 18 |
Why?
|
Transplantation, Homologous | 2 | 2002 | 94 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 2 | 2005 | 6 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 32 |
Why?
|
Diarrhea | 1 | 2009 | 41 |
Why?
|
Hematologic Diseases | 1 | 2009 | 23 |
Why?
|
Glucocorticoids | 1 | 2011 | 107 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2009 | 17 |
Why?
|
Esophagogastric Junction | 1 | 2009 | 10 |
Why?
|
Comorbidity | 2 | 2005 | 190 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2010 | 28 |
Why?
|
Chemokine CXCL10 | 1 | 2009 | 22 |
Why?
|
Oligopeptides | 1 | 2010 | 56 |
Why?
|
Benzopyrans | 1 | 2009 | 6 |
Why?
|
Guideline Adherence | 1 | 2010 | 64 |
Why?
|
Platinum Compounds | 1 | 2009 | 7 |
Why?
|
Drug Therapy, Combination | 2 | 1999 | 189 |
Why?
|
Vitamin D Deficiency | 1 | 2009 | 27 |
Why?
|
Multiple Myeloma | 1 | 2010 | 44 |
Why?
|
Fatal Outcome | 1 | 2009 | 86 |
Why?
|
Nitriles | 1 | 2009 | 27 |
Why?
|
Forecasting | 1 | 2010 | 147 |
Why?
|
Atrial Fibrillation | 1 | 2010 | 40 |
Why?
|
Antigens, CD | 2 | 2002 | 128 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2010 | 67 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2009 | 49 |
Why?
|
SEER Program | 1 | 2009 | 22 |
Why?
|
Daunorubicin | 1 | 2008 | 10 |
Why?
|
Predictive Value of Tests | 3 | 2003 | 321 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2009 | 55 |
Why?
|
Research Personnel | 1 | 2008 | 17 |
Why?
|
Databases as Topic | 1 | 2008 | 27 |
Why?
|
Cancer Care Facilities | 1 | 2008 | 14 |
Why?
|
Time Factors | 4 | 2004 | 896 |
Why?
|
Echocardiography | 1 | 2009 | 93 |
Why?
|
Yttrium Radioisotopes | 1 | 2008 | 1 |
Why?
|
Endoplasmic Reticulum | 1 | 2009 | 59 |
Why?
|
Bone Marrow Purging | 1 | 2008 | 5 |
Why?
|
Drugs, Investigational | 1 | 2008 | 8 |
Why?
|
Myeloid Cells | 1 | 2008 | 9 |
Why?
|
Breast Neoplasms | 2 | 2002 | 185 |
Why?
|
Italy | 1 | 2008 | 22 |
Why?
|
Graft Survival | 3 | 2002 | 74 |
Why?
|
Sinusitis | 1 | 2008 | 22 |
Why?
|
Chemokine CCL2 | 1 | 2009 | 57 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2008 | 10 |
Why?
|
Immunoglobulin Class Switching | 1 | 2008 | 17 |
Why?
|
Cytogenetics | 1 | 2008 | 13 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 71 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2008 | 32 |
Why?
|
Drug Monitoring | 1 | 2008 | 33 |
Why?
|
HIV Seropositivity | 1 | 2008 | 24 |
Why?
|
Antibody Formation | 1 | 2009 | 89 |
Why?
|
Biopsy, Fine-Needle | 1 | 2008 | 17 |
Why?
|
Genes, myc | 1 | 2008 | 22 |
Why?
|
Positron-Emission Tomography | 1 | 2008 | 32 |
Why?
|
CD4 Lymphocyte Count | 1 | 2008 | 50 |
Why?
|
Epitopes | 1 | 2008 | 86 |
Why?
|
Radiotherapy Dosage | 1 | 2008 | 55 |
Why?
|
Pyrimidines | 1 | 2008 | 49 |
Why?
|
Piperazines | 1 | 2008 | 57 |
Why?
|
Health Status Indicators | 1 | 2008 | 66 |
Why?
|
Data Collection | 1 | 2008 | 137 |
Why?
|
Immunocompromised Host | 1 | 2008 | 70 |
Why?
|
Gene Rearrangement | 2 | 2002 | 26 |
Why?
|
Bleomycin | 2 | 2003 | 28 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2008 | 53 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 55 |
Why?
|
Introns | 1 | 2008 | 58 |
Why?
|
Interferon-gamma | 1 | 2009 | 133 |
Why?
|
Leukemia, Myeloid | 1 | 2008 | 37 |
Why?
|
Immunologic Memory | 1 | 2008 | 51 |
Why?
|
Time | 1 | 2006 | 41 |
Why?
|
Radiotherapy | 1 | 2008 | 73 |
Why?
|
Tumor Markers, Biological | 1 | 2009 | 112 |
Why?
|
Liver | 1 | 2011 | 248 |
Why?
|
Hypertension | 1 | 2009 | 161 |
Why?
|
Psittacosis | 1 | 2005 | 2 |
Why?
|
Chlamydophila psittaci | 1 | 2005 | 3 |
Why?
|
Eye Neoplasms | 1 | 2005 | 17 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2008 | 53 |
Why?
|
Molecular Biology | 1 | 2006 | 38 |
Why?
|
Proteins | 1 | 2009 | 192 |
Why?
|
Immunohistochemistry | 1 | 2009 | 355 |
Why?
|
Brain Neoplasms | 1 | 2008 | 116 |
Why?
|
Complement C1q | 1 | 2005 | 8 |
Why?
|
Cell Division | 1 | 2008 | 273 |
Why?
|
Hospitalization | 2 | 1993 | 169 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 188 |
Why?
|
STAT1 Transcription Factor | 1 | 2004 | 11 |
Why?
|
Blood Component Removal | 1 | 2003 | 8 |
Why?
|
Iodine Radioisotopes | 1 | 2004 | 64 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2003 | 11 |
Why?
|
Cause of Death | 2 | 2001 | 82 |
Why?
|
Risk | 2 | 2001 | 203 |
Why?
|
Random Allocation | 1 | 2004 | 160 |
Why?
|
Fluorine Radioisotopes | 1 | 2003 | 7 |
Why?
|
Infusions, Intravenous | 1 | 2003 | 87 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 294 |
Why?
|
Proportional Hazards Models | 2 | 2001 | 123 |
Why?
|
Administration, Oral | 1 | 2004 | 170 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2003 | 12 |
Why?
|
Schizophrenia | 2 | 1993 | 48 |
Why?
|
Radiopharmaceuticals | 1 | 2003 | 37 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2002 | 14 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2002 | 14 |
Why?
|
Antigens, CD56 | 1 | 2002 | 16 |
Why?
|
Eosinophils | 1 | 2002 | 30 |
Why?
|
Histocompatibility | 1 | 2002 | 15 |
Why?
|
Lymphoma, T-Cell | 1 | 2002 | 12 |
Why?
|
Breast Implants | 1 | 2002 | 9 |
Why?
|
Pleural Effusion | 1 | 2001 | 24 |
Why?
|
Positive-Pressure Respiration | 1 | 2001 | 18 |
Why?
|
Analysis of Variance | 2 | 1998 | 339 |
Why?
|
Pneumonectomy | 1 | 2001 | 15 |
Why?
|
Biological Markers | 1 | 2004 | 262 |
Why?
|
Epidemiologic Methods | 1 | 2001 | 46 |
Why?
|
Ontario | 1 | 2001 | 12 |
Why?
|
Lymph Node Excision | 1 | 2001 | 30 |
Why?
|
Thyroglossal Cyst | 1 | 1981 | 6 |
Why?
|
Laser Therapy | 1 | 2001 | 27 |
Why?
|
Tongue Neoplasms | 1 | 1981 | 6 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2001 | 29 |
Why?
|
Choristoma | 1 | 1981 | 20 |
Why?
|
Thyroid Gland | 1 | 1981 | 40 |
Why?
|
Risk Assessment | 2 | 1999 | 324 |
Why?
|
Reoperation | 1 | 2001 | 106 |
Why?
|
Gene Expression | 1 | 2004 | 291 |
Why?
|
Sensitivity and Specificity | 1 | 2004 | 427 |
Why?
|
Cell Differentiation | 1 | 2006 | 262 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2002 | 91 |
Why?
|
Octreotide | 1 | 1999 | 5 |
Why?
|
Indium Radioisotopes | 1 | 1999 | 4 |
Why?
|
Sarcoma, Synovial | 1 | 1999 | 3 |
Why?
|
Abdominal Neoplasms | 1 | 1999 | 20 |
Why?
|
Thigh | 1 | 1999 | 18 |
Why?
|
Chondrosarcoma | 1 | 1999 | 14 |
Why?
|
Karyotyping | 1 | 1999 | 47 |
Why?
|
Medical Records | 2 | 2008 | 104 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 33 |
Why?
|
Hematopoietic Stem Cells | 1 | 2002 | 69 |
Why?
|
Liver Neoplasms | 1 | 1999 | 97 |
Why?
|
Bone Neoplasms | 1 | 1999 | 83 |
Why?
|
Prospective Studies | 3 | 2002 | 545 |
Why?
|
Statistics, Nonparametric | 1 | 1998 | 141 |
Why?
|
Cell Line, Tumor | 2 | 2009 | 208 |
Why?
|
Enzyme Inhibitors | 2 | 2009 | 216 |
Why?
|
Infant, Newborn | 3 | 1981 | 389 |
Why?
|
Lung Neoplasms | 1 | 1999 | 159 |
Why?
|
Holoprosencephaly | 1 | 1995 | 1 |
Why?
|
Nose Diseases | 1 | 1995 | 4 |
Why?
|
Nasal Obstruction | 1 | 1995 | 6 |
Why?
|
Logistic Models | 2 | 2004 | 251 |
Why?
|
Reproducibility of Results | 2 | 2008 | 391 |
Why?
|
Respiratory Sounds | 1 | 1994 | 15 |
Why?
|
Bronchoscopy | 1 | 1994 | 27 |
Why?
|
Esophagoscopy | 1 | 1994 | 22 |
Why?
|
Posture | 1 | 1994 | 68 |
Why?
|
Balloon Dilation | 1 | 1994 | 42 |
Why?
|
Patient Admission | 1 | 1994 | 72 |
Why?
|
Leukocyte Count | 1 | 1993 | 94 |
Why?
|
Syndrome | 1 | 1993 | 142 |
Why?
|
Wisconsin | 1 | 1992 | 6 |
Why?
|
Length of Stay | 1 | 1994 | 166 |
Why?
|
Lung | 1 | 1999 | 232 |
Why?
|
Injections, Intra-Arterial | 1 | 2011 | 28 |
Why?
|
Sex Factors | 1 | 1993 | 284 |
Why?
|
History, 20th Century | 1 | 1992 | 111 |
Why?
|
Diagnosis, Differential | 1 | 1994 | 402 |
Why?
|
Reed-Sternberg Cells | 1 | 2010 | 5 |
Why?
|
Microdissection | 1 | 2010 | 7 |
Why?
|
Paraffin Embedding | 1 | 2010 | 13 |
Why?
|
Tissue Fixation | 1 | 2010 | 13 |
Why?
|
Formaldehyde | 1 | 2010 | 18 |
Why?
|
Disease Management | 1 | 2010 | 23 |
Why?
|
Chymotrypsin | 1 | 2010 | 10 |
Why?
|
Benzenesulfonates | 1 | 2010 | 8 |
Why?
|
Benzamides | 1 | 2010 | 11 |
Why?
|
DNA, Neoplasm | 1 | 2010 | 75 |
Why?
|
Calcifediol | 1 | 2009 | 7 |
Why?
|
Dihydroxycholecalciferols | 1 | 2009 | 8 |
Why?
|
Societies, Medical | 1 | 2011 | 90 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2010 | 35 |
Why?
|
Clone Cells | 1 | 2010 | 92 |
Why?
|
Nutrition Policy | 1 | 2009 | 12 |
Why?
|
Mice, Nude | 1 | 2010 | 72 |
Why?
|
Seasons | 1 | 2009 | 64 |
Why?
|
Dietary Supplements | 1 | 2009 | 34 |
Why?
|
Diagnostic Imaging | 1 | 2010 | 66 |
Why?
|
Lymphoproliferative Disorders | 1 | 2009 | 23 |
Why?
|
DNA Damage | 1 | 2010 | 66 |
Why?
|
Cladribine | 1 | 2008 | 7 |
Why?
|
Blast Crisis | 1 | 2008 | 12 |
Why?
|
Immunity, Cellular | 1 | 2009 | 85 |
Why?
|
Cell Cycle | 1 | 2010 | 121 |
Why?
|
Observer Variation | 1 | 2008 | 103 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2008 | 34 |
Why?
|
Multivariate Analysis | 1 | 2010 | 225 |
Why?
|
Evidence-Based Medicine | 1 | 2009 | 125 |
Why?
|
Case-Control Studies | 1 | 2010 | 283 |
Why?
|
Registries | 1 | 2008 | 83 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2007 | 35 |
Why?
|
Blotting, Western | 1 | 2010 | 275 |
Why?
|
Dacarbazine | 1 | 2007 | 18 |
Why?
|
Severity of Illness Index | 1 | 2011 | 358 |
Why?
|
Enzyme Activation | 1 | 2009 | 177 |
Why?
|
Polyethylene Glycols | 1 | 2007 | 45 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 243 |
Why?
|
Bone Marrow | 1 | 2008 | 109 |
Why?
|
Thrombocytopenia | 1 | 2007 | 46 |
Why?
|
Neutropenia | 1 | 2007 | 42 |
Why?
|
Mitochondria | 1 | 2010 | 100 |
Why?
|
Transfection | 1 | 2010 | 237 |
Why?
|
NF-kappa B | 1 | 2010 | 114 |
Why?
|
DNA, Bacterial | 1 | 2005 | 67 |
Why?
|
Prednisolone | 1 | 2004 | 21 |
Why?
|
Radiation-Protective Agents | 1 | 2004 | 28 |
Why?
|
Chi-Square Distribution | 1 | 2004 | 179 |
Why?
|
Cytokines | 1 | 2007 | 207 |
Why?
|
Bone Marrow Cells | 1 | 2004 | 92 |
Why?
|
Radiotherapy, High-Energy | 1 | 2002 | 16 |
Why?
|
Silicone Gels | 1 | 2002 | 6 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2002 | 85 |
Why?
|
Microspheres | 1 | 2002 | 40 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2002 | 12 |
Why?
|
Tissue Donors | 1 | 2002 | 41 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2002 | 11 |
Why?
|
Hyoid Bone | 1 | 1981 | 3 |
Why?
|
Mediastinal Neoplasms | 1 | 1981 | 21 |
Why?
|
Survivors | 1 | 2002 | 45 |
Why?
|
Pilot Projects | 1 | 2002 | 264 |
Why?
|
Mice | 1 | 2010 | 623 |
Why?
|
Constriction, Pathologic | 1 | 1995 | 65 |
Why?
|
Intubation, Intratracheal | 1 | 1995 | 50 |
Why?
|
Animals | 1 | 2010 | 1031 |
Why?
|
